Trial Profile
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs GX 188E (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-567
- Sponsors Genexine
- 20 Jan 2023 Status changed from active, no longer recruiting to completed, according to a Genexine media release.
- 20 Jan 2023 According to a Genexine media release, the company received Fast Track Designation (FTD) from the Korean Ministry of Food and Drug Safety (MFDS) for GX-188E (tirvalimogene teraplasmid), based on data from this trial.
- 13 Sep 2022 Results assessing Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer presented at the 47th European Society for Medical Oncology Congress